In mice, Dr. Satchi-Fainaro's drugs were able to inhibit about half of all growth of drug-resistant tumors. In other, more drug-sensitive, tumors, "[We] basically eradicated the tumor or tumor metastasis, or got them back to dormant size -- about one millimeter," she says.

"I'm very realistic," she says. "If I can regress the massive angiogenesis, and get [tumors] to regress to dormant size, it's basically transforming cancer into a chronically manageable disease, like diabetes. As long as we have drugs that are non-toxic, we can keep the tumors at this size and live like that [taking the drugs]."


Dr. Satchi-Fainaro thinks this "tumor dormancy model" will be most appropriate for populations like women with mutations to the BRCA1 or BRCA2 genes, who have such a high risk for deadly breast cancer they often have both their breasts removed in precautionary double mastectomies. "To those women," Dr. Satchi-Fainaro says, "this can be a much better physical prophylactic treatment."

Currently, Dr. Satchi-Fainaro is licensing this treatment to a pharmaceutical company (she won't say which), and is also trying to figure out why cancers seem to thrive in bones. "That's the six million dollar question," she says.


Back to HCB News

More Industry Headlines